Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System

<div>The cost-effectiveness acceptability curves for apatinib strategies with or without PAP compared to the control strategy. The <i>y</i>-axis indicates the probability that a strategy is cost-effective across the WTP per QALY gained threshold (<i>x</i>-axis). The bold vertical dashed line represents the threshold for China.</div>

Gastroenterology Research and Practice

fig4

Figure 4

Figure 4: Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System 

Figure 4 | Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System 